Coffee break tip: Cathie Wood’s ARK funds just doubled down on Intellia Therapeutics, a gene-editing company that’s been on a wild ride—down after a clinical trial tragedy, but now up over 30% this year. Why does it matter? If you’re into stocks that could shake up medicine (think: CRISPR gene editing for rare heart disease), keep an eye on Intellia. Retail traders are buzzing, and sometimes following the crowd pays off—just don’t forget your own research! #Business #Market #CathieWood